Efficacy and Tolerability Evaluation of Nutraceutical Composition Containing Mucopolysaccharides, Collagen Type I, and Vitamin C in Tendinopathy: An Open-Label, Real-World Clinical Study

Background

Tendinopathy is characterized by pain, inflammation, and functional impairment with standard therapies supporting short-term symptomatic improvement. Nutraceuticals have emerged as potential adjuncts in tendon repair and symptom management. This study aimed to evaluate the efficacy and tolerability of a combination of mucopolysaccharides, collagen type I, and vitamin C in participants with tendinopathy.

Materials and Methods

Participants with clinically diagnosed tendinopathy were enrolled and assigned to either a standard therapy group (n=29) or active group (n=30). All participants received standard treatments, while the active group additionally received the test nutraceutical combination for 90 days. Symptom severity, including pain (at rest and during activity), stiffness, inflammation, mobility difficulty, weakness, and impact on daily and physical activity, along with Quality of Life (QoL), were assessed.

Results

Both groups demonstrated significant improvements; however, the active group showed a significantly greater reduction in pain at rest (92.37% v/s. 69.53%), pain during activity (87.55% v/s. 40.31%), stiffness (87.05% v/s. 44.25%), and weakness (78.50% v/s. 45.07%) (all p<0.05). Improvements in daily and physical activities were also greater in the active group. Inflammation and mobility showed numerically better outcomes, though not statistically significant. No adverse effects were reported in either group.

Conclusion

Supplementation with mucopolysaccharides, collagen type I, and vitamin C appears to enhance symptom relief and functional recovery in tendinopathy, supporting its use as a safe and effective adjunctive strategy.